SCHEDULE: Nuo Therapeutics Loan Agreement Amendment

Scott M. Pittman amends Schedule 13D regarding Nuo Therapeutics, detailing loan agreements and warrant issuances.

Summary

• Scott M. Pittman has filed an amendment (Amendment No. 4) to Schedule 13D concerning Nuo Therapeutics, Inc. common stock.
• This filing details amendments to loan agreements, specifically an Amended and Restated Loan and Security Agreement dated May 29, 2026.
• Pittman loaned $200,000 on January 23, 2026, and an additional $100,000 on May 29, 2026, under these agreements.
• The loan agreements bear interest at an annual rate of 12% and mature on December 31, 2028.
• Interest is payable in warrants, not cash, with principal repayment in quarterly installments starting March 31, 2027.
• The company can prepay the loans with certain fees and conditions, including mandatory prepayment upon equity financing of $5 million or more, change in control, or default.
• Various types of warrants (Commitment, Origination, Capital, Second, Prepayment, and Interest Warrants) have been issued or are issuable to lenders, including Pittman.
• The exercise price for all warrants is $1.50 per share of Common Stock.
• As of May 29, 2026, Pittman beneficially owns 5,627,500 shares of Common Stock, representing 11.6% of the outstanding shares.
• This ownership includes directly held shares, shares issuable from vested warrants, and shares issuable from options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While it secures necessary funding and outlines repayment terms, the reliance on debt with warrant sweeteners and potential for dilution indicates ongoing financial challenges and increased leverage.

Positives

• The company has secured additional funding through loan agreements, demonstrating continued financial support.
• The interest rate on the loans has been clarified and set at 12% annually.
• Warrants issued as part of the loan agreements provide potential upside for lenders if the company's stock price increases.
• The company has a clear repayment schedule for the principal starting in March 2027.
• Pittman's beneficial ownership of 11.6% indicates significant stakeholder commitment.

Negatives

• The company is reliant on debt financing, which increases financial leverage and risk.
• Interest payments are made in warrants, which can dilute existing shareholders.
• The company faces mandatory prepayment obligations triggered by equity financings, change in control, or default, indicating potential financial distress or strategic limitations.
• The exercise price of $1.50 for warrants may be significantly above the current market price if the stock is trading lower.

Risks

• The company's ability to repay the principal and interest on the notes by the December 31, 2028 maturity date is a key risk.
• A mandatory prepayment event, such as an equity financing of $5 million or more, could strain the company's cash resources.
• A change in control event could trigger a mandatory prepayment, impacting the company's strategic flexibility.
• Default by the company would lead to mandatory prepayment with a significant fee, potentially exacerbating financial difficulties.
• The issuance of numerous warrants could lead to significant dilution for existing shareholders upon exercise.

Future Outlook

The filing does not provide explicit forward-looking financial guidance. However, the structure of the loan agreements, including principal repayment schedules and maturity dates, outlines the company's financial obligations and repayment plan through December 31, 2028. The issuance of warrants suggests an expectation of future stock price appreciation.

Industry Context

StockSavvy.ai notes that this filing reflects a common financing strategy for early-stage or development-stage companies in the biotechnology sector, where access to traditional bank loans may be limited. The use of debt with equity-like features (warrants) is a way to secure capital while aligning lender incentives with potential future equity value. This approach is often seen when companies are advancing clinical trials or product development.

Comparison to Industry Standards

• Biotechnology companies often utilize convertible debt or debt with warrants to finance operations, especially during pre-revenue or early-revenue stages. This is comparable to how companies like Moderna or BioNTech may have structured early-stage financing.
• The interest rate of 12% is within the typical range for high-risk, venture debt or bridge loans in the biotech sector, which can range from 8% to 15% or higher depending on the company's stage and risk profile.
• The issuance of warrants as a financing sweetener is a standard practice. The percentage of dilution from warrants can vary significantly, but the terms here (e.g., 20-25% coverage for Capital Warrants) are not unusual for this type of financing.
• The exercise price of $1.50 per share is a critical factor. If the company's stock is trading significantly below this price, the warrants may not be exercised, impacting the company's ability to raise further capital through warrant exercises or the lenders' potential returns.

Related Party Transactions

• Scott M. Pittman, the reporting person, is also a lender to Nuo Therapeutics, Inc., providing loans and receiving warrants as part of these transactions.

Stakeholder Impact

• Shareholders: Potential dilution from the exercise of numerous warrants issued to lenders. The company's ability to meet debt obligations impacts future equity value.
• Creditors: The loan agreement places a lien on all company assets, potentially impacting the priority of other creditors.
• Lenders (including Pittman): Receive interest in the form of warrants and have secured debt, with potential for significant returns if the company's stock performs well.

Next Steps

• The company must manage its operations to meet the principal repayment schedule starting March 31, 2027.
• The company may need to seek additional equity financing of at least $5 million, which would trigger mandatory loan repayment.
• Lenders, including Scott M. Pittman, may exercise their warrants if the stock price exceeds $1.50 per share.
• The company must adhere to covenants and representations within the loan agreements.

Key Dates

Recommendation

The filing details ongoing financing arrangements and the issuance of warrants, which are standard for companies in this sector but introduce dilution risk. While the company is securing necessary capital, the terms suggest financial pressures. A 'hold' recommendation is appropriate pending further clarity on operational progress and the company's ability to manage its debt obligations and avoid significant dilution.

Keywords

Nuo Therapeutics, Schedule 13D, Scott M. Pittman, Loan Agreement, Warrants, Securities, Financing, Beneficial Ownership, Common Stock, Amendment